Oculis Secures $100 Million through Oversubscribed Share Offering
Oculis Holding AG, a prominent player in the biopharmaceutical industry, has recently made a significant announcement regarding its latest financial move. The company has announced an oversubscribed offering of 5 million ordinary shares priced at $20.00 per share, generating gross proceeds of $100 million. This funding will primarily support its clinical development pipeline focused on addressing critical ophthalmic conditions.
Use of Proceeds and Pipeline Development
The proceeds from the offering will be instrumental in advancing the company’s clinical programs. Oculis is particularly keen on accelerating the development of its novel neuroprotective candidate, Privosegtor (OCS-05), which aims to address acute optic neuritis and potentially other neuro-ophthalmic diseases. This move highlights Oculis' commitment to tackling significant unmet medical needs in the field of eye care.
Clinical Candidates in Focus
Oculis’ innovative pipeline showcases a variety of promising product candidates. Besides Privosegtor, it includes OCS-01, designed for diabetic macular edema, and Licaminlimab (OCS-02) intended for dry eye disease. These products aim to improve patient outcomes and set new standards in treatment efficacy.
Offering Details
This underwritten offering is expected to close shortly, pending customary closing conditions. Notably, the shares will come from Oculis' existing capital band, increasing the total number of registered shares to over 53 million, which reflects a proactive approach to capital management.
Collaboration with Financial Partners
To facilitate this offering, Oculis has partnered with leading financial institutions. BofA Securities and Leerink Partners serve as joint bookrunning managers, while Pareto Securities leads the management efforts. Arctica Finance is additionally acting as a financial advisor. This collaboration with trusted partners reinforces Oculis's strategic approach to funding its innovative projects.
Investing in the Future
The funding obtained through this offering will not only bolster Oculis’ ability to advance its clinical candidates but also support its corporate operations and working capital. By strengthening its financial base, Oculis is positioned to accelerate its research and development efforts, ensuring that it remains at the forefront of eye care innovation.
Oculis and Its Vision for Eye Care
With its headquarters in Switzerland, and additional operations in the U.S. and Iceland, Oculis is led by a management team with extensive experience in the biopharmaceutical industry. Their mission is clear: to save sight and enhance eye care through cutting-edge science. As a Nasdaq and Iceland-listed company (NaSDaq: OCS; Iceland: OCS), Oculis remains committed to its vision of transforming the landscape of ophthalmic treatments.
Company Contacts
For more information on this offering or company inquiries, interested parties may contact:
Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
Frequently Asked Questions
What is the purpose of Oculis's recent share offering?
The recent share offering is aimed at enhancing Oculis's clinical development pipeline, particularly for its candidate Privosegtor (OCS-05) and other innovative treatments.
How much money is Oculis raising through this offering?
Oculis aims to raise $100 million through the underwritten offering of 5 million ordinary shares.
What are the main products in Oculis's pipeline?
The main products in Oculis's pipeline include OCS-01 for diabetic macular edema, Privosegtor (OCS-05) for acute optic neuritis, and Licaminlimab (OCS-02) for dry eye disease.
When is the expected closing date for the offering?
The offering is expected to close shortly, around February 18, 2025, subject to standard closing conditions.
Who are the financial partners involved in the offering?
BofA Securities and Leerink Partners are the joint bookrunning managers, while Pareto Securities and Arctica Finance also play key roles in the offering process.
